The pivotal role of microRNA-155 in the control of cancer

Journal of Cellular Physiology

Volumn 229, Issue 5, 2014, Pages 545-550

  Chen, Zhaolin ^a   Ma, Taotao ^a   Huang, Cheng ^a   Hu, Tingting ^a   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DICER; EXPORTIN 5; MESSENGER RNA; MICRORNA; MICRORNA 155; RIBONUCLEASE III; RNA; RNA INDUCED SILENCING COMPLEX;

3' UNTRANSLATED REGION; BREAST CANCER; CANCER CONTROL; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; EPIGENETICS; HUMAN; IMMUNITY; LIVER CELL CARCINOMA; LUNG CANCER; NEOPLASM; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RNA DEGRADATION;

ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS;

EID: 84892663478     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24492     Document Type: Review

References (75)

1. Bakirtzi K, Hatziapostolou M, Karagiannides I, Polytarchou C, Jaeger S, Iliopoulos D, Pothoulakis C. 2011. Neurotensin signaling activates microRNAs-21 and -155 and Akt, promotes tumor growth in mice, and is increased in human colon tumors. Gastroenterology 141:1749-1761, e1741.
2. Bartel DP. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
3. Berenguer J, Herrera A, Vuolo L, Torroba B, Llorens F, Sumoy L, Pons S. 2013. MicroRNA 22 regulates cell cycle length in cerebellar granular neuron precursors. Mol Cell Biol 33:2706-2717.
4. Breving K, Esquela-Kerscher A. 2010. The complexities of microRNA regulation: Mirandering around the rules. Int J Biochem Cell Biol 42:1316-1329.
5. Brosh R, Shalgi R, Liran A, Landan G, Korotayev K, Nguyen GH, Enerly E, Johnsen H, Buganim Y, Solomon H, Goldstein I, Madar S, Goldfinger N, Borresen-Dale AL, Ginsberg D, Harris CC, Pilpel Y, Oren M, Rotter V. 2008. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol 4:229.
6. Chang S, Wang RH, Akagi K, Kim KA, Martin BK, Cavallone L, Haines DC, Basik M, Mai P, Poggi E, Isaacs C, Looi LM, Mun KS, Greene MH, Byers SW, Teo SH, Deng CX, Sharan SK. 2011. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med 17:1275-1282.
7. Chen J, Wang BC, Tang JH. 2012. Clinical significance of microRNA-155 expression in human breast cancer. J Surg Oncol 106:260-266.
8. Costinean S, Sandhu SK, Pedersen IM, Tili E, Trotta R, Perrotti D, Ciarlariello D, Neviani P, Harb J, Kauffman LR, Shidham A, Croce CM. 2009. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 114:1374-1382.
9. Davis-Dusenbery BN, Hata A. 2010. MicroRNA in cancer: The involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer 1:1100-1114.
10. di Iasio MG, Norcio A, Melloni E, Zauli G. 2012. SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155. Invest New Drugs 30:2403-2406.
11. Du ZM, Hu LF, Wang HY, Yan LX, Zeng YX, Shao JY, Ernberg I. 2011. Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PloS ONE 6:e19137.
12. Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H. 2013. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem 59:1489-1496.
13. Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE. 2005. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 102:3627-3632.
14. Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F, Lo-Coco F. 2012. MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: Correlation with NPM1 and FLT3 mutation status. J Hematol Oncol 5:26.
15. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. 2013. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia. Blood 122:1891-1899.
16. Filipowicz W, Bhattacharyya SN, Sonenberg N. 2008. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 9:102-114.
17. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, Chaix A, Fazli L, Motoo Y, Wang Q, Rocchi P, Russo A, Gleave M, Dagorn JC, Iovanna JL, Carrier A, Pebusque MJ, Dusetti NJ. 2007. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 104:16170-16175.
18. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. 2010. Elevated expression of microRNAs 155, 203 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 126:73-80.
19. Guo H, Ingolia NT, Weissman JS, Bartel DP. 2010. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466:835-840.
20. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. 2012. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 138:153-161.
21. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. 2012. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer 130:1378-1386.
22. Hellebrekers DM, Castermans K, Vire E, Dings RP, Hoebers NT, Mayo KH, Oude Egbrink MG, Molema G, Fuks F, van Engeland M, Griffioen AW. 2006. Epigenetic regulation of tumor endothelial cell anergy: Silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 66:10770-10777.
23. Huang X, Shen Y, Liu M, Bi C, Jiang C, Iqbal J, McKeithan TW, Chan WC, Ding SJ, Fu K. 2012. Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. Am J Pathol 181:26-33.
24. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065-7070.
25. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF, Wang ED. 2010. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70:3119-3127.
26. Jiang S, Zhang LF, Zhang HW, Hu S, Lu MH, Liang S, Li B, Li Y, Li D, Wang ED, Liu MF. 2012. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J 31:1985-1998.
27. Kim JH, Kim WS, Park C. 2012. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leuk Lymphoma 53:1586-1591.
28. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ. 2010. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem 285:17869-17879.
29. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ. 2013. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene.
30. Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ. 2008. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 28:6773-6784.
31. Kono H, Nakamura M, Ohtsuka T, Nagayoshi Y, Mori Y, Takahata S, Aishima S, Tanaka M. 2013. High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. Oncol Rep 30:17-24.
32. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. 2002. Identification of tissue-specific microRNAs from mouse. Curr Biol 12:735-739.
33. Levati L, Alvino E, Pagani E, Arcelli D, Caporaso P, Bondanza S, Di Leva G, Ferracin M, Volinia S, Bonmassar E, Croce CM, D'Atri S. 2009. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol 35:393-400.
34. Levati L, Pagani E, Romani S, Castiglia D, Piccinni E, Covaciu C, Caporaso P, Bondanza S, Antonetti FR, Bonmassar E, Martelli F, Alvino E, D'Atri S. 2011. MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res 24:538-550.
35. Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, Yan M, Qu QL, Zhu ZG, Liu BY. 2012a. microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol Rep 27:1960-1966.
36. Li S, Chen T, Zhong Z, Wang Y, Li Y, Zhao X. 2012b. microRNA-155 silencing inhibits proliferation and migration and induces apoptosis by upregulating BACH1 in renal cancer cells. Mol Med Rep 5:949-954.
37. Liu Q, Chen J, Wang J, Amos C, Killary AM, Sen S, Wei C, Frazier ML. 2013a. Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma. Mol Carcinog.
38. Liu WJ, Zhao YP, Zhang TP, Zhou L, Cui QC, Zhou WX, You L, Chen G, Shu H. 2013b. MLH1 as a direct target of miR-155 and a potential predictor of favorable prognosis in pancreatic cancer. J Gastrointest Surg 17:1399-1405.
39. Lu Z, Ye Y, Jiao D, Qiao J, Cui S, Liu Z. 2012. miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status. Oncol Lett 4:1027-1032.
40. Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P, Rodriguez-Padilla C, Resendez-Perez D. 2013. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers 34:163-169.
41. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD. 2013. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 31:2086-2093.
42. Matysiak M, Fortak-Michalska M, Szymanska B, Orlowski W, Jurewicz A, Selmaj K. 2013. MicroRNA-146a negatively regulates the immunoregulatory activity of bone marrow stem cells by targeting prostaglandin E2 synthase-2. J Immunol 190:5102-5109.
43. Mavrakis KJ, Leslie CS, Wendel HG. 2011. Cooperative control of tumor suppressor genes by a network of oncogenic microRNAs. Cell Cycle 10:2845-2849.
44. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. 2004. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chr Cancer 39:167-169.
45. Nana-Sinkam SP, Croce CM. 2013. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 93:98-104.
46. Noren Hooten N, Abdelmohsen K, Gorospe M, Ejiogu N, Zonderman AB, Evans MK. 2010. microRNA expression patterns reveal differential expression of target genes with age. PloS ONE 5:e10724.
47. O'Hara AJ, Wang L, Dezube BJ, Harrington WJ, Jr., Damania B, Dittmer DP. 2009. Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood 113:5938-5941.
48. Peng Y, Xiang H, Chen C, Zheng R, Chai J, Peng J, Jiang S. 2013. MiR-224 impairs adipocyte early differentiation and regulates fatty acid metabolism. Int J Biochem Cell Biol 45:1585-1593.
49. Pillai RS, Bhattacharyya SN, Filipowicz W. 2007. Repression of protein synthesis by miRNAs: How many mechanisms? Trends Cell Biol 17:118-126.
50. Pouliot LM, Chen YC, Bai J, Guha R, Martin SE, Gottesman MM, Hall MD. 2012. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res 72:5945-5955.
51. Pu J, Bai D, Yang X, Lu X, Xu L, Lu J. 2012. Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155. Biochem Biophys Res Commun 428:210-215.
52. Qin W, Ren Q, Liu T, Huang Y, Wang J. 2013. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett 587:1434-1439.
53. Rai D, Kim SW, McKeller MR, Dahia PL, Aguiar RC. 2010. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 107:3111-3116.
54. Rather MI, Nagashri MN, Swamy SS, Gopinath KS, Kumar A. 2013. Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: Implications for cancer therapeutics. J Biol Chem 288:608-618.
55. Saito Y, Suzuki H, Tsugawa H, Imaeda H, Matsuzaki J, Hirata K, Hosoe N, Nakamura M, Mukai M, Saito H, Hibi T. 2012. Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PloS ONE 7:e47396.
56. Sandhu SK, Volinia S, Costinean S, Galasso M, Neinast R, Santhanam R, Parthun MR, Perrotti D, Marcucci G, Garzon R, Croce CM. 2012. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Emu-miR-155 transgenic mouse model. Proc Natl Acad Sci USA 109:20047-20052.
57. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, Greenberg ME. 2006. A brain-specific microRNA regulates dendritic spine development. Nature 439:283-289.
58. Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. 2010. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 79:313-320.
59. Sontheimer EJ. 2005. Assembly and function of RNA silencing complexes. Nat Rev Mol Cell Biol 6:127-138.
60. Tam W, Ben-Yehuda D, Hayward WS. 1997. bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding RNA. Mol Cell Biol 17:1490-1502.
61. Tili E, Michaille JJ, Croce CM. 2013. MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 253:167-184.
62. Vasilatou D, Papageorgiou S, Pappa V, Papageorgiou E, Dervenoulas J. 2010. The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 84:1-16.
63. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, Dunant A, Pham TC, Petrini I, Lee A, Khan MA, Hainaut P, Pignon JP, Brambilla E, Popper HH, Filipits M, Harris CC, Giaccone G. 2010. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 70:8288-8298.
64. Vrba L, Munoz-Rodriguez JL, Stampfer MR, Futscher BW. 2013. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PloS ONE 8:e54398.
65. Wang J, Wu J. 2012. Role of miR-155 in breast cancer. Front Biosci (Landmark Ed) 17:2350-2355.
66. Yan XL, Jia YL, Chen L, Zeng Q, Zhou JN, Fu CJ, Chen HX, Yuan HF, Li ZW, Shi L, Xu YC, Wang JX, Zhang XM, He LJ, Zhai C, Yue W, Pei XT. 2013. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: Role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology 57:2274-2286.
67. Yang M, Shen H, Qiu C, Ni Y, Wang L, Dong W, Liao Y, Du J. 2013. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer 49:604-615.
68. Zang YS, Zhong YF, Fang Z, Li B, An J. 2012. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther 19:773-778.
69. Zhang C, Zhao J, Deng H. 2013a. 17beta-estradiol up-regulates miR-155 expression and reduces TP53INP1 expression in MCF-7 breast cancer cells. Mol Cell Biochem 379:201-211.
70. Zhang P, Bill K, Liu J, Young E, Peng T, Bolshakov S, Hoffman A, Song Y, Demicco EG, Terrada DL, Creighton CJ, Anderson ML, Lazar AJ, Calin GG, Pollock RE, Lev D. 2012a. MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer Res 72:1751-1762.
71. Zhang X, Li M, Zuo K, Li D, Ye M, Ding L, Cai H, Fu D, Fan Y, Lv Z. 2013b. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/beta-catenin signaling. J Clin Endocrinol Metab 98:E1305-E1313.
72. Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM. 2012b. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 120:1678-1686.
73. Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, Sun S. 2012c. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 56:1631-1640.
74. Zhao XD, Zhang W, Liang HJ, Ji WY. 2013. Overexpression of miR-155 promotes proliferation and invasion of human laryngeal squamous cell carcinoma via targeting SOCS1 and STAT3. PloS ONE 8:e56395.
75. Zonari E, Pucci F, Saini M, Mazzieri R, Politi LS, Gentner B, Naldini L. 2013. A role for miR-155 in enabling tumor-infiltrating innate immune cells to mount effective antitumor responses in mice. Blood 122:243-252.